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Down-regulation of  nitric oxide synthase (NOS) and NO defi ciency in the kidneys have 
been implicated in the pathogenesis of  chronic kidney disease (CKD). In this study 
we examined the effects of  losartan, tempol, and combined treatment on three NOS 
isoforms expressions, kidney NO content and NOS correlation with renal function 
and structure in the early stage of  adriamycin (ADR)-induced CKD in spontaneously 
hypertensive rats (SHR). Rats were divided into control group, and four other groups 
which were treated with ADR and received vehicle, losartan (L, angiotensin II type 1 
receptor blocker), tempol (T, redox-cycling nitroxide) or T+L treatment (by gavage) in a 
six-week study. Reduction of  all NOS isoforms expressions were signifi cantly improved 
by losartan or tempol, and correlated with proteinuria amelioration. Combined 
treatment induced down-regulation of  constitutive NOS isoforms, whilst inducible 
NOS was up-regulated and followed by increased nitrite content and a signifi cant 
decline in the glomerular fi ltration rate. Losartan or tempol prevented ADR-induced 
neoexpression of  vimentin in the glomeruli and tubulointerstital areas, whereas de novo 
vimentin expression was still observed in the atrophic tubules and in the interstitial 
fi broblasts and myofi broblasts in combined treatment. It can be concluded that single 
treatments, contrary to combined, were effective in improving NO bioavailability and 
slowing down the progression of  CKD.
Key words: adriamycin nephropathy, hypertension, nitric oxide synthase, losartan, 
tempol
INTRODUCTION
Nitric oxide (NO) is a free radical molecule formed by the conversion of  L-agrinine 
to L-citruline by NO synthase (NOS) [1], has multiple roles involving cell signaling, 
vasodilatation, infl ammation, tissue injury and cell defense [1,2]. In the kidney, NO 
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is implicated in the regulation of  glomerular capillary pressure, glomerular fi ltration 
and renal blood fl ow [2,3]. All three isoforms of  NOS, endothelial NOS (eNOS), 
neuronal NOS (nNOS) and inducible NOS (iNOS), have been identifi ed in the kidney 
[4,5]. The constitutive forms of  NOS, eNOS and nNOS, produce small quantities 
of  NO, which is important for the regulation of  glomerular microcirculation and the 
inhibition of  platelet aggregation and adhesion, whereas iNOS, which can be induced 
by various cytokines and endotoxins, produces large quantities of  NO with cytotoxic 
effects [2]. In the kidney constitutive NOS isoforms are expressed in physiological 
conditions, eNOS is mainly distributed in glomerular endothelial cells, afferent and 
efferent arterioles, and vasa recta in the medulla [2], whereas nNOS is restricted to 
the macula densa, efferent arterioles and Bowman’s capsule [6]. The iNOS was found 
mainly in the tubules in the normal renal tissue [7-9].
NOS defi ciency and decrease in NO production occur by multiple mechanisms and 
contribute to the pathogenesis and progression of  chronic kidney disease (CKD) [10]. 
Previous studies reported that the inhibition of  eNOS, nNOS or iNOS, either by using 
a selective inhibitor or knockout mice for particular enzyme, exacerbate renal injury and 
accelerate the progression of  glomerular damage and proteinuria in different animal 
models of  CKD [9,11-15]. Down-regulation of  nNOS expression and following 
decrease of  urinary nitrate/nitrite content were ameliorated by an angiotensin II type 
1 receptor (AT1R) blocker, losartan in nephrectomized (5/6 Nx) rats [16]. Captopril, 
angiotensin-converting enzyme inhibitor (ACEI), also caused an increase in urinary 
excretion of  NO products and abrogated proteinuria and hypertension in the 5/6 
Nx rats [7], pointing to a direct relationship between angiotensin II (AngII) and renal 
NOS in CKD.
It has been shown that antioxidant treatment in rats with renal ablation (5/6 Nx) 
reverse down-regulations of  NOS isoforms [5], prevent superoxide production 
[17], and protect against renal dysfunction and injury [18], presumably by reducing 
oxidative stress. Furthermore, tempol, a cell permeable redox-cycling nitroxide [19], 
elicited higher increase of  renal eNOS expression than losartan, and showed an anti-
infl ammatory effect associated with antioxidant action in the kidneys of  rats submitted 
to sodium overload [20].
Previous studies performed by this group of  authors showed that spontaneously 
hypertensive rats (SHR) with adriamycin (ADR)-induced nephropathy, when 
treated with captopril [21] or losartan [22,23] improved hypertension, one of  the 
factors involved in CKD progression. The second risk factor responsible for CKD 
progression, proteinuria, was also attenuated with losartan in the early phase of  the 
disease, followed by improvement of  oxidative stress, tubular structure and restoration 
of  anti-infl ammatory defense, however, tempol was more successful in reducing 
systemic oxidative stress, proteinuria and glomerulosclerosis [23]. Interestingly, 
combined treatment did not overcome these benefi ts of  single treatments in slowing 
down the progression of  CKD, probably because it failed to improve bioavailability of  
NO in this experimental model.
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Thus, the aim of  the present study was to investigate the effects of  chronic single and 
combined treatments with losartan and tempol on renal NOS isoforms expressions 




Adult female SHR (six-month-old, 180-200 g body weight (b.w.)) were housed under 
standard conditions at the Institute for Medical Research, Belgrade, Serbia. Tap water 
and standard rat chow (Veterinarski zavod Subotica, Serbia) were provided ad libitum. 
The experimental protocol was in accordance with the National Law on Animal 
Welfare (“Sl.gl.RS” No6/10) and approved by the Ethic Committee of  the Institute 
for Medical Research, University of  Belgrade, Serbia and Veterinary Directorate, 
Ministry of  Agriculture and Environmental Protection, Republic of  Serbia (No. 
323-07-00318/2015-05). All surgical interventions were performed under anesthesia 
(sodium pentobarbital, 35 mg/kg b.w., intraperitoneally (i.p.)), and all efforts were 
made to minimize suffering.
The rats were randomly divided into fi ve groups according to previous non-invasive 
(Physiograph Four, Narco Bio-system Houston, TX, USA) systolic blood pressure 
measurement. Four experimental groups received ADR (2 mg/kg b.w.) twice in a 21-
day interval, intravenously (femoral vein) under anesthesia. Control group (SHC) was 
injected with a comparable volume of  0.9% saline. After the second injection of  saline 
or ADR, SHC and SHADR received tap water, while SHADR+L, SHADR+T, and 
SHADR+T+L groups received losartan (L, 10 mg/kg/day b.w., Dup 753, DuPont, 
Wilmington De.), tempol (T, 100 mg/kg/day b.w., Sigma-Aldrich), or both (T+L) by 
gavage during the next six weeks, respectively. At the end of  the study, rats were 
placed in individual metabolic cages for 24-hour urine collection. After this period, 
blood pressure measurement, followed by blood sample and kidney collection were 
performed on anaesthetized animals.
Blood pressure
Mean blood pressure (MBP) was measured in anesthetized rats as previously described 
[23].
Sample collection
Blood samples were obtained by abdominal aorta puncture, using an anticoagulant-
EDTA (Ethylenediaminetetraacetic acid disodium salt dehydrate, Division of  ICN 
Biomedicals, Inc.Cleveland, Ohio) and centrifuged at 4000 rpm, 4°C for 20 min. 
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Plasma was collected and stored at -20°C until assaying. Kidneys were harvested, 
weighted and stored at -70°C for later analysis.
Estimation of kidney function parameters
Urine and plasma creatinine, as well as urine protein concentrations were measured 
by an automatic COBAS INTEGRA 400 plus analyzer (Hoffmann-La Roche, 
Leitch Diagnostic, Germany). Creatinine clearance (Ccr) was assessed to evaluate the 
glomerular fi ltration rate (GFR), and calculated according to a standard formula. Urine 
protein excretion (Pexc, mg/min/kg) was used for the assessment of  proteinuria.
Immunohistochemisry
Immunostaining was applied on 5 μm thick paraffi n sections as previously described 
[23]  using primary antibodies: nNOS (Chemicon International, AB5380, dilution 
1:100), iNOS (Sigma-Aldrich, SAB4502011, dilution 1:100), eNOS (Invitrogen 
by Thermo Fisher Scientifi c, PA1-037, dilution 1:100), and vimentin (Millipore, 
MAB3400, dilution 1:200).
Western blotting
For Western blotting the kidneys were homogenized in lysis buffer, as previously 
described [23] and stored at -70°C until analysis. Equal amounts of  protein samples 
were run on 8% polyacrylamide gels and transferred to nitrocellulose membranes 
(Appli-Chem GmbH, Darmstadt, Germany). Membranes were probed with primary 
antibodies to nNOS (1:1000, AB5380 Chemicon International), iNOS (1:1000, 
SAB4502011 Sigma-Aldrich), eNOS (1:1000, PA1-037 Invitrogen by Thermo Fisher 
Scientifi c), and actin (1:1000, Sigma-Aldrich, A5060). Peroxidase-conjugated goat anti-
rabbit immunoglobulin (1:40.000, Sigma-Aldrich, A0545) was used as the secondary 
antibody. Western blots were developed using the enhanced chemiluminescence 
reagent system (GE Healthcare, Amersham, UK) according to the manufacturer’s 
instructions. The content of  the target proteins in the tissue extracts were estimated 
by the densitometry of  scanned immunoblot bands using the Image Master Total Lab 
(GE Healthcare) software.
Determination of NO levels in kidney homogenates
Kidney homogenates were assayed for NOx content by the Griess reagent method 
[24]. Nitrate reductase (NAD[P]H) from Aspergillus niger was used for conversion of  
nitrate (NO3
-) to nitrite (NO2
-).
Statistical analysis
Data are presented as mean ± SEM. One-way analysis of  variance (ANOVA) was 
used for multiple comparisons between experimental groups, and Fisher LSD test was 
Karanovic et al.: Effects of  losartan, tempol, and their combination on renal nitric oxide synthases in the animal model of  chronic kidney disease
413
performed as post hoc multiple comparison test (Statistica 8). The Pearson correlation 
between the examined parameters was also determined. P-value < 0.05 was considered 
signifi cant.
RESULTS
Blood pressure and kidney function
MBP and parameters of  renal function are presented in Table 1. ADR did not affect 
MBP or Ccr in SHR with early stage of  ADR nephropathy. MBP was signifi cantly 
reduced only in the SHADR+L group compared to both SHC and SHADR. Massive 
proteinuria was observed in SHADR group, and it was signifi cantly reduced following 
all treatments. However, the levels of  Pexc in SHADR+L and SHADR+T+L groups 
were signifi cantly higher than in SHC, while in SHADR+T it was almost similar to 
control group. Contrary to both single treatments, losartan and tempol in combination 
(SHADR+T+L) induced a signifi cant reduction of  Ccr compared to SHC and 
SHADR+T group.
Immunoperoxidase staining and western blot analysis of iNOS,
nNOS, and eNOS
Immunohistochemical localization of  eNOS was mainly detected in the glomeruli 
of  studied groups (Figure 1A-E). In control group glomerular endothelial cells 
were positively stained for eNOS (Figure 1A). In contrast, in SHADR group eNOS 
staining was clearly lower, whereas it was hardly detected in the area of  mesangial 
expansion of  glomeruli with moderate lesions or in the sclerotic glomeruli (Figure 
1B). The extent of  staining for eNOS after losartan treatment was clearly increased 
in the glomeruli (Figure 1C). The expression pattern of  eNOS in the renal tissue of  
SHADR+T group was similar to that in SHADR+L group (Figure 1D). Combined 
treatment showed lower, almost completely absent eNOS in the glomeruli (Figure 
1E). The nNOS positive staining was prominent in the macula densa of  SHC group 
(Figure 1F), but only rarely observed in SHADR (Figure 1G), and strongly expressed 
in both SHADR+L and SHADR+T (Figure 1H, I), whereas in SHADR+T+L group 
the expression was clearly lower (Figure 1J). The iNOS positive staining was widely 
distributed in renal tubules. In the control group prominent iNOS staining was noticed 
in the proximal and distal tubules and collecting ducts (Figure 1K). In contrast, the 
iNOS immunostaining was lower in the renal tubules of  ADR-treated SHR (Figure 
1L). In epithelial tubular cells, losartan or tempol (Figure 1M, N) induced a strong 
positive iNOS staining, whereas combined treatment did not (Figure 1O).
Results obtained from the western blot studies of  nNOS, eNOS, and iNOS protein 
expressions are presented in Figure 2. The expression of  iNOS was signifi cantly 
suppressed, while nNOS and eNOS expressions were markedly, but not signifi cantly 
reduced in ADR-treated SHR. Losartan or tempol treatments signifi cantly increased 
the expressions of  all NOS isoforms in the kidney compared with the SHADR group.
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Figure 1. Immunohistochemical staining for NOS isoforms in renal tissue in the experimental 
groups. Original magnifi cation x40 in (A-J), scale bar = 100 μm; x20 in (K-O), scale bar = 200 
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μm. Immunohistochemistry for eNOS (A-E): In SHC group the eNOS positive staining is 
observed in glomerular endothelial cells (thick arrow) (A). In SHADR group eNOS staining 
is clearly lower and hardly detected in sclerotic glomerulus (B, left one); note the absence of  
eNOS staining in the area of  mesangial expansion (the area surrounded by thin arrows) in the 
upper-right glomerulus (B). The eNOS staining is clearly increased in glomeruli of  SHADR+L 
group (C). The expression pattern of  eNOS in the renal tissue of  SHADR+T (D) is similar to 
that in SHADR+L group (C). Combined treatment showed lower, almost completely absent 
of  glomerular eNOS expression (E). Immunohistochemistry for nNOS (F-J): In SHC group 
strong nNOS expression is observed in the macula densa (F). In SHADR group only rare 
cells are positive for nNOS in macula densa (G). The prominent nNOS staining is found 
in SHADR+L (H) and SHADR+T (I) groups, whereas in SHADR+T+L group the nNOS 
expression is clearly lower in macula densa (J). Immunohistochemistry for iNOS (K-O): The 
iNOS protein is widely distributed in renal tubular cells of  SHC group (K). The expression 
of  iNOS is lower in injured renal tubules of  SHADR group (J). The SHADR+L group (M) 
exhibits strong iNOS immunostaining in proximal and distal tubules and collecting ducts, 
and similar pattern is observed in SHADR+T (N). In SHADR+T+L (O) group the iNOS 
expression is clearly lower in areas with moderate renal injury. SHC – control group, SHADR 
– SHR treated with adriamycin, L – losartan, T – tempol, md – macula densa.
In addition, the eNOS expression was signifi cantly increased in both, SHADR+L 
and SHADR+T groups compared to the control group. Tempol induced a stronger 
increase (p < 0.05) of  iNOS expression than losartan. In contrast, the expressions of  
constitutive NOS isoforms in SHADR+T+L group were signifi cantly lower than that 
found in the control group, or after both single treatments, and similar to SHADR 
group. Furthermore, combined treatment signifi cantly increased the expression of  
iNOS in SHADR+T+L group to the level near the control group, even though it still 
remained signifi cantly lower than the one found in the SHADR+T group.
Figure 2. Kidney NOS isoforms protein levels in the experimental groups. (A) Representative 
Western blots showing specifi c band for iNOS, eNOS, nNOS, and actin as an internal control. 
The quantitative data, calculated as the relative density of  the target protein to that of  actin, are 
presented in (B-D): (B) iNOS, (C) eNOS, and (D) nNOS. *p < 0.05, **p < 0.01, ***p < 0.001 vs. 
SHC; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. SHADR; $$p < 0.01, $$$p < 0.001 vs. SHADR+L; 
&p < 0.05, &&&p < 0.001 vs. SHADR+T; n = 6 animals per group. Data represent mean ± SEM. 
SHC – control group, SHADR – SHR treated with adriamycin, L – losartan, T – tempol.
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Renal NO content
At the end of  the six-week period, a signifi cant reduction of  the NOx content, which 
was associated with a drop in nitrate level, was observed in the kidney of  the SHADR 
group (Table 1). Losartan reverted the NOx level to the control value. Contrary to the 
single treatment, tempol in combination with losartan induced a signifi cant increase of  
nitrite content, resulting in a strong rise of  NOx level (p < 0.05) compared to the value 
in the kidney of  SHADR group.











MBP (mmHg) 164.38 ± 10.46 160.63 ± 9.94 136.14 ± 4.67 *# 143.13 ± 8.77 144.75 ± 7.20
Ccr (ml/min/kg) 4.19 ± 0.46 3.58 ± 0.43 3.04 ± 0.31 3.98 ± 0.68 2.43 ± 0.56 
*&
Pexc (mg/min/kg) 0.02 ± 0.00 1.10 ± 0.24 
*** 0.51 ± 0.09 **## 0.18 ± 0.03 ### 0.38 ± 0.08 *###
NO3
- (μmol/mg prot) 76.57 ± 5.29 56.30 ± 5.59 * 65.50 ± 5.04 54.99 ± 5.67 * 71.90 ± 8.44
NO2
- (μmol/mg prot) 4.57 ± 0.56 5.09 ± 0.35 6.80 ± 0.97 4.88 ± 0.36 8.55 ± 1.48 **##&&
NOx (μmol/mg prot) 81.14 ± 5.32 61.39 ± 5.67 
* 72.30 ± 5.65 59.88 ± 5.78 * 80.45 ± 9.66 #&
MBP – mean blood pressure, Ccr – creatinine clearance,  Pexc – protein urine excretion, NOx – 
sum of  renal NO3
- and NO2
- content.
* p < 0.05, ** p < 0.01, *** p < 0.001 vs. SHC; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. SHADR, 
& p < 0.05, && p < 0.01vs. SHADR+T;  
n = 8 animals per group. Data represent mean ± SEM. SHC – control group, SHADR – SHR 
treated with adriamycin, L – losartan, T – tempol.
Immunolocalization of vimentin
Control group showed normal expression of  vimentin in the glomeruli, predominantly 
in the podocytes, arterioles, and in occasional interstitial fi broblasts (Figure 3A, F), 
and the epithelial cells of  the tubules were negative (Figure 3K). In ADR-treated 
SHR increased vimentin expression was observed in the podocytes, mesangial cells, 
and parietal epithelial cells of  Bowman’s capsule in the sclerotic glomeruli (Figure 
3B, G). In addition, vimentin neoexpression was observed in the tubulointerstitial 
areas, where dedifferentiated tubular epithelial cells, fi broblasts and myofi broblasts 
stained positive for vimentin (Figure 3L). Both single treatments either with 
losartan (Figure 3C, H) or tempol (Figure 3D, I) clearly decreased vimentin 
expression in all glomeruli, while tubules were negative for vimentin (Figure 3M, 
N). Positive vimentin immunostaining was observed in glomeruli of  SHADR+T+L 
group (Figure 3E, J) in a similar pattern as in SHADR+T and SHADR+L groups, 
while immunodistribution of  vimentin in interstitial fi broblasts and myofi broblasts 
(Figure 3O) of  this group were the same, but with lower intensity compared to SHADR 
group. Furthermore, moderate de novo expression of  vimentin in the dedifferentiated 
tubules was observed in SHADR+T+L group (Figure 3O) compared to SHADR 
group (Figure 3L). 
Karanovic et al.: Effects of  losartan, tempol, and their combination on renal nitric oxide synthases in the animal model of  chronic kidney disease
417
Figure 3. Immunohistochemical staining for vimentin in the renal tissue in the experimental 
groups. Original magnifi cation: x20 in (A-E), scale bar = 200 μm; and x40 in (nc, F-O), scale 
bar = 100 μm. In SHC group the normal vimentin expression is observed in podocytes (thick 
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arrows) (A, F), while epithelial cells of  the tubules do not show expression of  vimentin (K). 
In the SHADR group increased vimentin expression is observed in the podocytes, mesangial 
cells, and in the parietal epithelial cells of  Bowman’s capsule (thick arrows) of  the sclerotic 
glomeruli (B, G). Notice the neoexpression of  vimentin in the tubulointerstitial areas, where 
dedifferentiated tubular epithelial cells, fi broblasts and myofi broblasts (thin arrows) stain 
positive for vimentin (L). Losartan clearly decrease vimentin expression in all glomeruli (C, H) 
and tubules are negative for vimentin (M) in SHADR+L group. Similar pattern of  vimentin 
expression is also found in SHADR+T group (D, I, N). In SHADR+T+L group moderate 
de novo vimentin expression is observed in the proximal tubules, whereas in the interstitium 
fi broblasts and myofi broblasts (thin arrows) were stained positive for vimentin (O), while 
in glomeruli (E, J) vimentin is expressed similarly as in SHADR+T (I) and SHADR+L (H) 
groups. SHC – control group, SHADR – SHR treated with adriamycin, L – losartan, T – 
tempol, nc – negative control staining.
Correlation analysis of parameters
The correlations among the examined parameters are presented in Table 2. Proteinuria 
was negatively correlated with the expression of  nNOS, eNOS, and iNOS. In addition, 
there was a strong positive correlation between three NOS isoforms in the kidneys. 
MBP was not in correlation with proteinuria nor NOS isoforms expression in this 
experimental model.
Table 2. The correlation among MBP, Pexc, and renal NOS protein expression in all experimental groups
 MBP (mmHg) iNOS/actin eNOS/actin nNOS/actin
Pexc (mg/min/kg) r = 0.0032 r = -0.4020 r = -0.3750 r = -0.4383
p = 0.987 p = 0.028 p = 0.041 p = 0.015
iNOS/actin r = -0.1910 r = 0.7399 r = 0.6526
p = 0.312 p = 0.000 p = 0.000
eNOS/actin r = -0.3407 r = 0.7399 r = 0.8455
p = 0.065 p = 0.000 p = 0.000
nNOS/actin r = -0.0798 r = 0.6526 r = 0.8455
 p = 0.675 p = 0.000 p = 0.000  
MBP – mean blood pressure, Pexc – protein urine excretion, NOS – nitric oxide synthase, n – 
neuronal, i - inducible, e – endothelial. Marked correlations are signifi cant at p < 0.05, N = 30.
DISCUSSION
In the present study, we demonstrated that the expression of  NOS isoforms in the 
kidney were strongly depressed in the early stage of  ADR nephropathy. Simultaneous 
down-regulations of  all NOS isoforms expression were signifi cantly improved by the 
treatment with AT1R blocker (losartan) or antioxidant (tempol) showing a strong 
correlation with proteinuria amelioration in ADR-treated SHR. In contrast, when used 
in combination losartan and tempol induced a signifi cant increase of  iNOS expression 
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and no changes in diminished expression of  nNOS and eNOS in SHADR+T+L 
group. The NOS defi ciency in the SHADR group was followed by a signifi cant 
reduction of  NOx content in the kidney, which was restored by losartan. Contrary to 
single treatment, tempol in combination with losartan induced a signifi cant increase 
of  nitrite level in the renal tissue. Furthermore, even though combined treatment 
lowered proteinuria, a signifi cant fall in GFR still existed in SHADR+T+L group. To 
our knowledge, this is the fi rst study of  renal distribution of  three NOS isoforms, as 
well as vimentin after combined and single losartan and tempol treatments, pointing 
to a relationship between NOS attenuation and the progression of  kidney disease in 
SHR with an early stage of  ADR nephropathy.
The fi ndings are in accordance with previous reports from Rangan et al., who showed 
that continuous oral administration of  two structurally diverse selective inhibitors 
of  iNOS exacerbated the progression of  ADR-induced nephropathy indicating that 
endogenous iNOS-derived NO has a protective role in proteinuric tubulointerstitial 
injury [12]. Moreover, the inhibition of  iNOS by aminoguanidine resulted with more 
structural changes in the renal cortex of  diabetic rats [9]. The eNOS defi ciency 
exacerbates renal injury in the remnant kidney model [25] and accelerates diabetic kidney 
damage [14,26]. Likewise, Sun et al. showed that glomerular endothelial dysfunction 
and damage precede podocyte damage in ADR-induced nephropathy in C57BL/6 
mice with eNOS defi ciency [11], indicating the importance of  glomerular endothelial 
cells in the pathogenesis of  proteinuria and development of  glomerulosclerosis, 
tubulointerstitial fi brosis and infl ammation. Furthermore, the reduction in nNOS 
protein abundance correlates with increasing glomerular damage and decreasing 
renal function in different animal models of  CKD [13,27,28], suggesting that the 
renal nNOS response to kidney damage may be an important determinant of  the 
susceptibility to CKD progression.
Podocytes in the glomerulus express three intermediate fi lament proteins, namely 
nestin, vimentin, and desmin, which are up-regulated in puromycin aminonucleoside 
nephrosis [29]. We have recently (2016) documented overexpression and diffused 
glomerular distribution of  nestin in SHR with early ADR nephropathy [23]. In this 
study, vimentin was located predominantly in the podocytes of  SHR, and ADR 
application induced a strong up-regulation of  vimentin expression in the podocytes, 
mesangial cells, parietal epithelial cells of  Bowman’s capsule in the sclerotic glomeruli, 
and scattered peritubular positive staining areas were also observed. Likewise, with 
the same dose of  ADR, Van Beneden et al. showed the same pattern of  vimentin 
expression in Wistar rats [30]. These data lead to the conclusion that the preexistence 
of  hypertension in our model could not be accounted for glomerular and tubular 
remodeling in the early phase of  ADR nephropathy. Other studies have shown that 
the up-regulation of  vimentin expression was observed in the renal tubules and 
interstitial areas in cyclosporine A-induced nephrotoxicity [31,32]. Since vimentin is 
used as a marker of  tubulointerstitial injury and epithelial-mesenchymal transition, 
the neoexpression of  vimentin in the proximal tubules is an unequivocal signal of  
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injury and regeneration in these areas [31,33]. Furthermore, Bravo et al. showed that 
NOS inhibition by L-NAME induced a signifi cant increase of  vimentin expression 
in the kidneys of  Sprague-Dawley rats. These data are in agreement with our fi ndings 
of  vimentin distribution in SHADR kidney, and ADR-attenuated NOS expression 
points to the important role of  NO defi ciency in the pathogenesis and progression of  
renal disease in the early stage of  ADR nephropathy. All of  the treatments decreased 
vimentin expression in a signifi cant degree, while losartan and tempol single treatments 
showed greater effect in preventing vimentin positive staining in tubules of  ADR pre-
treated SHR rats.
In the present study, we showed that losartan, as a specifi c antagonist of  AT1 
receptors, besides the antihypertensive effect, induced a signifi cant improvement of  all 
three NOS isoforms expressions and restored NOx content in the kidney, which were 
associated with proteinuria amelioration in the SHADR+L group. Previous reports 
also indicated that the mechanism for impaired NO production in CKD may involve 
the renin angiotensin system (RAS). Namely, the 5/6 Nx-induced down-regulation of  
nNOS protein expression was partially restored in the renal cortex following treatment 
with losartan [16]. Losartan also normalized AngII expression and simultaneously 
enhanced eNOS expression in the renal cortex and medulla in rats submitted to 
sodium overload [20]. However, contrary to our study, Ji et al. showed that blocking 
RAS by losartan slowed the progression of  renal injury in rats subjected to unilateral 
nephrectomy and ADR injection, 6 mg/kg, by down-regulating the expression of  
iNOS [34]. Such discrepancy could be the result of  different experimental design and 
difference in dose of  ADR used to induce various degrees of  CKD.
eNOS defi ciency accelerates renal injury induced by 5/6 Nx [18] and it could be 
ameliorated by a combination of  L-arginine and antioxidants (vitamin C and E). 
Previous studies have reported similar results [5,17,20]. In this study, tempol induced a 
signifi cant increase of  all three NOS isoforms expressions and abolished proteinuria in 
SHR with ADR nephropathy, even though the nitrate level in the kidney was reduced. 
Our previous fi ndings showing that tempol increased urinary nitrate excretion [23] 
support this notion. Taking into account that renal NO production represents just a 
small fraction of  total NO [17], since the kidney is a minor source of  NO generation, 
dissociation between total and renal NO production was also observed in different 
forms of  CKD [2].
The major fi nding of  this study is that a combination of  losartan and tempol, contrary 
to single treatments, induced a down-regulation of  both constitutive NOS isoforms 
and a signifi cant increase of  iNOS expression, which was accompanied by a signifi cant 
increase of  nitrite production in the kidney of  SHR with ADR-induced nephropathy. 
In addition, in SHADR+T+L group proteinuria was lower compared to the SHADR 
group, but still signifi cantly higher than in the control group, and followed by a 
signifi cant decline of  GFR. Similar fi ndings were obtained by Furusu et al. who showed 
that the degree of  glomerular injury negatively correlated with eNOS and positively 
with iNOS expression in proliferative glomerulonephritis [4]. Nonetheless, Ozen et 
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al. suggested that increased production of  nitrite by iNOS might be responsible for 
proteinuria in ADR-induced nephropathy in Wistar rats [35]. Since the half-life of  NO 
is very short, the biological effects of  NO depend on the concentration at the site 
of  action and the specifi c location of  NO production. Based on the fact that small 
quantities of  NO are generated by constitutive NOS isoforms, while large quantities 
of  NO are synthesized by iNOS [2], we presume that in this study the signifi cantly 
increased nitrite level in the kidney is the consequence of  elevated iNOS activity with 
concurrent reduction of  both constitutive NOS isoforms in SHADR+T+L group. 
Thus, NO2
- could react with O2
- and yield peroxynitrite anion, which is a strong 
oxidant that could react with and modify various molecules, such as lipids, DNA, 
and proteins, causing structural and functional changes and leading to increased renal 
injury and progression of  kidney disease. Taken together, these fi ndings suggest that 
the combination of  AT1R blocker and tempol in ADR-induced nephropathy in SHR 
could induce the alteration in the expression of  NOS isoforms in the kidneys in a way 
that contributes to the progression of  renal disease. Our results also suggest that NOS 
could play a critical role in the pathogenic mechanisms of  progressive kidney disease 
and that NO may also participate in the process of  glomerular injury through different 
mechanisms.
In conclusion, in the early stage of  CKD in SHR, ADR caused down-regulation 
of  renal NOS isoforms expressions, defi ciency of  kidney NO content, vimentin 
neoexpression and massive proteinuria, independently of  blood pressure. Losartan 
or tempol single treatments, contrary to their combination, were more effective in 
ameliorating proteinuria, renal vimentin and NOS protein isoforms expressions and 
in slowing-down the progression of  CKD. Further studies are needed to clarify the 
exact mechanism of  interactions between AT1R blockade and tempol in stimulation 
of  renal NO pathway and their effects on slowing down the progression of  ADR 
nephropathy.
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EFEKTI LOSARTANA, TEMPOLA I NJIHOVE KOMBINACIJE 
NA EKSPRESIJU ENZIMA SINTEZE AZOT MONOKSIDA 
U BUBREZIMA U ANIMALNOM MODELU HRONIČNE 
BUBREŽNE SLABOSTI
KARANOVIC Danijela, GRUJIC-MILANOVIC Jelica, MILORADOVIC Zoran, 
IVANOV Milan, JOVOVIC Djurdjica, VAJIC Una-Jovana, CIROVIC Sanja, 
MARKOVIC-LIPKOVSKI Jasmina, MIHAILOVIC-STANOJEVIC Nevena
Snižena ekspresija enzima sinteze azotnog monoksida (NOS) kao i njegova smanjena 
raspoloživost u bubrezima mogu dovesti do progresije hronične bubrežne bolesti. Cilj 
ove studije je bio ispitati efekte losartana, tempola i kombinovane terapije na ekspresiju 
tri izoforme NOS, kao i povezanost NO sistema sa funkcijom i strukturom bubrega 
u ranoj fazi hronične bubrežne slabosti izazvane adrijamicinom (ADR) kod pacova 
sa urodjenom hipertenzijom. Pacovi su bili rasporedjeni u kontrolnu i još četiri grupe 
koje su bile tretirane ADR. Životinje su potom primale vodu, losartan (L, selektivni 
blokator angiotenzin II tip 1 receptora), tempol (T, stabilni nitroksid radikal) ili T+L 
(gavažom) tokom narednih šest nedelja. Smanjene ekspresije svih izoformi NOS 
izazvane ADR bile su značajno povećane nakon tretmana losartanom ili tempolom 
i praćene smanjenom proteinurijom. Kombinovani tretman je doveo do smanjene 
ekspresije konstitutivnih izoformi NOS, dok je povećanje ekspresije inducibilne NOS 
bilo praćeno povišenom koncentracijon nitrita u tkivu bubrega i značajnim smanjenjem 
glomerulske fi ltracije. Za razliku od kombinovanog, pojedinačni tretmani losartanom 
ili tempolom sprečili su de novo sintezu vimentina, izazvanu ADR, u glomerulima, 
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tubulima i intersticijumu. Zaključili smo da su pojedinačni tretmani, nasuprot 
kombinovanom, efi kasniji u očuvanju bioraspoloživosti NO, kao i usporavanju 
progresije hronične bubrežne slabosti.
